Evidence map›Paper›PMID 40172407›Full record

ArticleJornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia2025

Evaluation of the IMPROVE-DD score in COVID-19 patients submitted to venous thromboembolism investigation at a hospital in Brazil.

Ronney Argolo Ferreira, Lian Zanatta, Juliane Bispo de Oliveira, Janaina Ibele Carvalho Gomes, Luiz Ritt, Ana Thereza Cavalcanti Rocha

Abstract read
In one paragraph

Article in Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ronney Argolo Ferreira. Faculdade de Medicina, Universidade Federal da Bahia, Salvador (BA), Brasil.ORCID http://orcid.org/0000-0001-6619-2402
Lian Zanatta. Faculdade de Medicina, Universidade Federal da Bahia, Salvador (BA), Brasil.ORCID http://orcid.org/0000-0003-0290-9157
Juliane Bispo de Oliveira. Faculdade de Medicina, Universidade Federal da Bahia, Salvador (BA), Brasil.ORCID http://orcid.org/0000-0003-4129-3324
Janaina Ibele Carvalho Gomes. Faculdade de Medicina, Universidade Federal da Bahia, Salvador (BA), Brasil.ORCID http://orcid.org/0000-0002-1988-0699
Luiz Ritt. Escola Baiana de Medicina e Saúde Pública, Salvador (BA), Brasil.ORCID http://orcid.org/0000-0001-9320-7999
Ana Thereza Cavalcanti Rocha. Faculdade de Medicina, Universidade Federal da Bahia, Salvador (BA), Brasil.ORCID http://orcid.org/0000-0002-5321-2598

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the incidence of venous thromboembolism (VTE) in hospitalized patients with COVID-19 who underwent diagnostic tests for suspected VTE, and to correlate the IMPROVE-DD score with the incidence of VTE in this cohort.

methodsThis retrospective study included consecutive patients with COVID-19 and suspected VTE, admitted between March 2020 and September 2021 at a private hospital in Salvador (BA), Brazil, who underwent lower or upper limb venous Doppler ultrasound or chest angiotomography. Descriptive analyses and comparisons using the chi-square test were performed to identify factors potentially associated with the risk of VTE.

resultsA total of 517 patients were included, with an in-hospital VTE incidence of 18.6% (96 events). Risk factors significantly associated with VTE included obesity, ICU admission, central venous catheter use, longer hospital stays, greater lung tomographic involvement/severity, the need for mechanical ventilation, D-dimer levels at least twice the upper limit of normal (2xULN), and the IMPROVE-DD score. The mean IMPROVE-DD score among patients with VTE was 4.7 (±3) versus 3.3 (±2.4) in those without VTE (p < 0.0001). D-dimer 2xULN was sensitive in identifying 94% of the 96 patients with VTE (p < 0.0001). The in-hospital mortality rate was 14.1%, with higher rates observed in patients with VTE (24%) compared to those without VTE (11.9%) (p = 0.003).

conclusionsThe incidence of VTE in hospitalized COVID-19 patients was high and correlated with increased mortality. The IMPROVE-DD score effectively identified patients at risk for in-hospital VTE, suggesting it could help to identify a high-risk subgroup that may benefit from extended thromboprophylaxis.

Indexed as

COVID-19Venous ThromboembolismAdultAgedBrazilFemaleFibrin Fibrinogen Degradation ProductsHospitalizationHumansIncidenceLength of StayMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsFibrin Fibrinogen Degradation Productsfibrin fragment D

Identifiers

PMID40172407
PMCPMC12097741

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.